Intratracheal injection of dendritic cells loaded with cytotoxic T cell epitope of intracellular pathogen efficiently induces epitope-specific T cells and confers protective immunity

气管内注射负载细胞内病原体细胞毒性T细胞表位的树突状细胞,可有效诱导表位特异性T细胞并赋予保护性免疫

基本信息

  • 批准号:
    17590784
  • 负责人:
  • 金额:
    $ 2.24万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2005
  • 资助国家:
    日本
  • 起止时间:
    2005 至 2006
  • 项目状态:
    已结题

项目摘要

The present study was conducted to develop an effective mucosal cell-vaccine against infection of intracellular pathogen. Bone-marrow derived mouse dendritic cells were treated with LPS for 16 hrs, and pulsed with dominant cytotoxic T cell (CTL) epitope, LLO91-99, derived from lysteriolysin O of Listeria monocytogenesis (LM). Then, LLO-loaded dendritic cells were intratracheally instilled. Tracheal injection of LLO-loaded dendritic cells induced LLO-specific CTL determined by tetramers, and LLO-specific IFN-gamma production from regional lymph nodes. In a mouse model of pulmonary LM infection, vaccinated mouse showed a significant decrease in bacterial doses compared with naive mouse. Moreover, this dendritic cell-vaccine protected them from lethal LM infection. Taken together, these results suggest that intratracheal administration of dendritic cells loaded with a dominant CTL epitope against intracellular pathogen is an effective mucosal vaccine, which induces protective immunity the mucosal sites as well as systemic immunity.
本研究旨在研制一种有效的抗细胞内病原体感染的粘膜细胞疫苗。用LPS处理骨髓来源的小鼠树突细胞16小时,并用来源于单核细胞生成李斯特菌(LM)的溶血素O的显性细胞毒性T细胞(CTL)表位LLO 91 -99脉冲。然后,将负载LLO的树突状细胞进行气管内滴注。气管注射负载LLO的树突状细胞诱导由四聚体确定的LLO特异性CTL,以及局部淋巴结产生的LLO特异性IFN-γ。在肺部LM感染的小鼠模型中,与未接种小鼠相比,接种小鼠显示细菌剂量显著降低。此外,这种树突状细胞疫苗可以保护他们免受致命的LM感染。总之,这些结果表明,肠道内施用负载有针对细胞内病原体的优势CTL表位的树突状细胞是有效的粘膜疫苗,其诱导粘膜部位的保护性免疫以及全身免疫。

项目成果

期刊论文数量(21)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Quantitative analysis of fibroblastic foci in usual interstitial pneumonia
  • DOI:
    10.1378/chest.130.1.22
  • 发表时间:
    2006-07-01
  • 期刊:
  • 影响因子:
    9.6
  • 作者:
    Enomoto, Noriyuki;Suda, Takafumi;Chida, Kingo
  • 通讯作者:
    Chida, Kingo
Identification of HLAA*0201-Restricted T-Cell Epitope on MPT51 Protein, a Major Secreted Protein Derived from Mycobacterium tuberculosis using MPT5 1 Overlappin, Peptides Screening.
使用 MPT5 1 Overlappin、肽筛选鉴定 MPT51 蛋白(结核分枝杆菌衍生的主要分泌蛋白)上的 HLAA*0201 限制性 T 细胞表位。
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Aoshi T;Nagata T;Suzuki M;et. al.
  • 通讯作者:
    et. al.
Correlation between peripheral blood T-cell profiles and airway inflammation in atopic asthma.
外周血 T 细胞谱与特应性哮喘气道炎症之间的相关性。
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Shirai T;Inui N;Suda T;et. al.
  • 通讯作者:
    et. al.
alpha-Galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation.
Lung dendritic cells have a potent capability to induce production 0f immunoglobulin A.
肺树突状细胞具有诱导产生 0f 免疫球蛋白 A 的强大能力。
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Naito T;Suda T;Suzuki K;et. al.
  • 通讯作者:
    et. al.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SUDA Takafumi其他文献

SUDA Takafumi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SUDA Takafumi', 18)}}的其他基金

Novel dendritic cell vaccine for tuberculosis with inhibition of indoleamine 2, 3-dioxygenase.
抑制吲哚胺 2, 3-双加氧酶的新型结核病树突状细胞疫苗。
  • 批准号:
    21590985
  • 财政年份:
    2009
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of dendritic cell vaccine modified with a ligand of NKT cells against tuberculosis
开发用 NKT 细胞配体修饰的抗结核树突状细胞疫苗
  • 批准号:
    19590888
  • 财政年份:
    2007
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of anti-tuberculosis vaccine using cytokine gene-transduced dendritic cells
使用细胞因子基因转导的树突状细胞开发抗结核疫苗
  • 批准号:
    15590803
  • 财政年份:
    2003
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of DC-vaccine against tuberclulosis
抗结核 DC 疫苗的研制
  • 批准号:
    13670595
  • 财政年份:
    2001
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Involvement of dendritic cells in pulmonary granuloma formation elicited by BCG in rats
树突状细胞参与卡介苗诱导的大鼠肺肉芽肿形成
  • 批准号:
    11670572
  • 财政年份:
    1999
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Understanding of causal links between gut microbiota and mucosal vaccine efficacy
了解肠道微生物群与粘膜疫苗功效之间的因果关系
  • 批准号:
    23K13877
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection
一种针对铜绿假单胞菌感染的新型粘膜疫苗
  • 批准号:
    10446501
  • 财政年份:
    2022
  • 资助金额:
    $ 2.24万
  • 项目类别:
NOVEL MUCOSAL VACCINE APPROACHES FOR PNEUMONIA.
肺炎的新型粘膜疫苗方法。
  • 批准号:
    10710590
  • 财政年份:
    2022
  • 资助金额:
    $ 2.24万
  • 项目类别:
Optimization for Zika virus oral mucosal vaccine using recombinant saccharomyces and lactobacilli
使用重组酵母菌和乳酸杆菌优化寨卡病毒口腔粘膜疫苗
  • 批准号:
    22K10495
  • 财政年份:
    2022
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel Nanoparticle Respiratory Tract Mucosal Vaccine
新型纳米颗粒呼吸道粘膜疫苗
  • 批准号:
    10442173
  • 财政年份:
    2022
  • 资助金额:
    $ 2.24万
  • 项目类别:
Novel Nanoparticle Respiratory Tract Mucosal Vaccine
新型纳米颗粒呼吸道粘膜疫苗
  • 批准号:
    10599198
  • 财政年份:
    2022
  • 资助金额:
    $ 2.24万
  • 项目类别:
NOVEL MUCOSAL VACCINE APPROACHES FOR PNEUMONIA KLEBSIELLA
治疗克雷伯氏肺炎的新型粘膜疫苗方法
  • 批准号:
    10863795
  • 财政年份:
    2022
  • 资助金额:
    $ 2.24万
  • 项目类别:
A Novel Mucosal Vaccine for Pseudomonas aeruginosa Infection
一种针对铜绿假单胞菌感染的新型粘膜疫苗
  • 批准号:
    10550157
  • 财政年份:
    2022
  • 资助金额:
    $ 2.24万
  • 项目类别:
A Novel Th17-inducing Mucosal Vaccine for Tuberculosis
一种新型 Th17 诱导型结核粘膜疫苗
  • 批准号:
    10757098
  • 财政年份:
    2020
  • 资助金额:
    $ 2.24万
  • 项目类别:
Development of a mucosal vaccine to prevent Clostridium difficile infection using papilloma pseudovirus as a vector.
使用乳头状瘤假病毒作为载体开发粘膜疫苗以预防艰难梭菌感染。
  • 批准号:
    10213890
  • 财政年份:
    2020
  • 资助金额:
    $ 2.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了